Evidence map›Paper›PMID 41026418›Full record

ArticleJournal of neuro-oncology2025

Sacituzumab govitecan and stereotactic radiosurgery in the management of HER2 negative breast cancer brain metastases: a multi-institutional report.

Vaseem M Khatri, Mariella A Mestres-Villanueva, Sierra Daniel, Sreenija Yarlagadda, Ajay Doniparthi, Rituraj Upadhyay, Matthew N Mills, Daniel E Oliver, Hsiang-Hsuan Michael Yu, Joshua D Palmer and 10 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Brain metastasis: Opportunities for novel therapies.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
    Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Vaseem M KhatriDepartment of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Dr, Tampa, FL, 33612, USA.
Mariella A Mestres-VillanuevaDepartment of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH, 43201, USA.
Sierra DanielDepartment of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH, 43201, USA.
Sreenija YarlagaddaDepartment of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL, 33176, USA.
Ajay DoniparthiUniversity of South Florida Morsani College of Medicine Tampa, Tampa, FL, 33602, USA.
Rituraj UpadhyayDepartment of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Dr, Tampa, FL, 33612, USA.
Matthew N MillsDepartment of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Dr, Tampa, FL, 33612, USA.
Daniel E OliverDepartment of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Dr, Tampa, FL, 33612, USA.
Hsiang-Hsuan Michael YuDepartment of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Dr, Tampa, FL, 33612, USA.
Joshua D PalmerDepartment of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH, 43201, USA.
Daniel G StoverDepartment of Medical Oncology, The Ohio State University Wexner Medical Center, Columbus, OH, 43201, USA.
Nicole O WilliamsDepartment of Medical Oncology, The Ohio State University Wexner Medical Center, Columbus, OH, 43201, USA.
Reshma L MahtaniDepartment of Medical Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL, 33176, USA.
Manmeet S AhluwaliaDepartment of Medical Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL, 33176, USA.
Aixa E SoyanoDepartment of Breast Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, 33612, USA.
Hatem H SolimanDepartment of Breast Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, 33612, USA.
Hyo S HanDepartment of Breast Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, 33612, USA.
Rupesh KotechaDepartment of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL, 33176, USA.
Sasha J BeyerDepartment of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH, 43201, USA.
Kamran A AhmedDepartment of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Dr, Tampa, FL, 33612, USA. kamran.ahmed@moffitt.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeImproved treatment strategies are needed for HER2 negative breast cancer brain metastases (BCBM). Stereotactic radiosurgery (SRS) is the standard of care for limited brain metastases. Sacituzumab govitecan (SG) may have intracranial efficacy for BCBM; however, safety and efficacy data remain limited when combined with SRS.

methodsA multi-institutional retrospective review was performed of patients with HR+/HER2- and triple negative (TNBC) BCBM treated with SG and SRS for active BMs at three institutions. Concurrent SG and SRS was defined as SRS after the date of first SG infusion and before or on the date of last SG infusion. Safety was assessed as well as distant intracranial control (DIC), systemic and central nervous systemic (CNS) progression-free survival (PFS), local control (LC), and overall survival (OS).

resultsA total of 277 lesions were treated over 36 SRS courses in 26 patients. Median follow up from SG initiation was 23.3 months. One hundred sixty-eight (61%) lesions were treated with single fraction SRS and 109 (39%) lesions were treated with fractionated SRS (fSRS). One hundred thirty-five (47%) lesions received concurrent SRS and SG. No cases of symptomatic radiation necrosis (SRN) were noted. LC rates at 12- and 24-months were 94% and 84%, respectively. Median CNS-PFS was 5.4 months (95% CI 2.8-7.3). Median systemic PFS was 4.4 months (95% CI 2.2-7.3 months). Median overall survival was 8.4 months with a 24-month rate of 16%.

conclusionIn our series, concurrent SRS and SG was associated with excellent local control, without an increased risk of SRN. Prospective investigation into potential synergy is warranted.

Indexed as

Antibodies, Monoclonal, HumanizedBrain NeoplasmsBreast NeoplasmsCamptothecinRadiosurgeryAdultAgedAged, 80 and overCombined Modality TherapyErb-b2 Receptor Tyrosine KinasesFemaleFollow-Up StudiesHumansImmunoconjugatesMiddle AgedRetrospective StudiesAntibodies, Monoclonal, HumanizedCamptothecinERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesImmunoconjugatessacituzumab govitecanBrain metastasesBreast cancerSacituzumab govitecanStereotactic radiosurgery

Identifiers

PMID41026418

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.